ceftriaxone / BrainX Corp - LARVOL DELTA

To Assess the Efficacy and Safety of Ceftriaxone in Patients With Mild to Moderate Parkinson's Disease Dementia (clinicaltrials.gov) - P2 | N=100 | Active, not recruiting | Sponsor: BrainX Corporation | Trial completion date: Aug 2025 ➔ Dec 2025

Trial completion date • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia • Movement Disorders • Parkinson's Disease

To Assess the Efficacy and Safety of Ceftriaxone in Patients With Mild to Moderate Parkinson's Disease Dementia (clinicaltrials.gov) - P2 | N=100 | Active, not recruiting | Sponsor: BrainX Corporation | Recruiting ➔ Active, not recruiting | Trial completion date: Mar 2025 ➔ Aug 2025 | Trial primary completion date: Dec 2024 ➔ Jun 2025

Enrollment closed • Trial completion date • Trial primary completion date • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia • Movement Disorders • Parkinson's Disease • Aβ42

To Assess the Efficacy and Safety of Ceftriaxone in Patients With Mild to Moderate Parkinson's Disease Dementia (clinicaltrials.gov) - P2 | N=106 | Recruiting | Sponsor: BrainX Corporation | Trial completion date: Dec 2023 ➔ Mar 2025 | Trial primary completion date: Jun 2023 ➔ Dec 2024

Trial completion date • Trial primary completion date • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia • Movement Disorders • Parkinson's Disease

To Assess the Efficacy and Safety of Ceftriaxone in Patients With Mild to Moderate Parkinson's Disease Dementia (clinicaltrials.gov) - P2; N=106; Recruiting; Sponsor: BrainX Corporation; Trial completion date: May 2022 ➔ Dec 2023; Trial primary completion date: Dec 2021 ➔ Jun 2023

Clinical • Trial completion date • Trial primary completion date • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia • Movement Disorders • Parkinson's Disease • MRI

To Assess the Efficacy and Safety of Ceftriaxone in Patients With Mild to Moderate Parkinson’s Disease Dementia (clinicaltrials.gov) - P2; N=106; Recruiting; Sponsor: BrainX Corporation; Trial completion date: Dec 2020 ➔ May 2022; Trial primary completion date: Jul 2020 ➔ Dec 2021

Clinical • Trial completion date • Trial primary completion date • Alzheimer's Disease • CNS Disorders • Dementia • Gene Therapies • Movement Disorders • Parkinson's Disease • MRI